Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats

BackgroundCirculating plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration facilitates emergency diagnosis of congestive heart failure (CHF) in people. Its utility to discriminate between dyspneic cats with CHF vs. primary respiratory disease requires further assessment. Our objectives were to determine if NT-proBNP (1) differentiates dyspneic cats with CHF vs. primary respiratory disease; (2) increases with renal insufficiency; (3) correlates with left atrial dimension, radiographic cardiomegaly, and estimated left ventricular filling pressure (E/E_a).MethodsNT-proBNP was measured in 167 dyspneic cats (66 primary respiratory disease, 101 CHF) to evaluate (1) relationship with clinical parameters; (2) ability to distinguish CHF from primary respiratory disease; (3) optimal cut-off values using receiver operating characteristic (ROC) curve analysis.ResultsNT-proBNP (1) was higher (median and inter-quartile [25th–75th] percentile) in CHF (754 pmol/L; 437, 1035 pmol/L) vs. primary respiratory disease (76.5 pmol/L; 24, 180 pmol/L) cohorts (P < 0.001); (2) positively correlated in CHF cats with increased inter-ventricular septal end-diastolic thickness (ρ = 0.266; P = 0.007) and LV free wall thickness (ρ = 0.218; P = 0.027), but not with radiographic heart size, left atrial size, left ventricular dimensions, E/E_a ratio, BUN, creatinine, or thyroxine; (3) distinguished dyspneic CHF cats from primary respiratory disease at 265 pmol/L cut-off value with 90.2% sensitivity, 87.9% specificity, 92% positive predictive value, and 85.3% negative predictive value (area under ROC curve, 0.94).ConclusionsNT-proBNP accurately discriminated CHF from respiratory disease causes of dyspnea.     

Effectiveness of a non-surgical alternative to the Mules operation in sheep

Objective To measure changes to the perineal bare area, local tissue reaction and healing responses of young sheep, following intradermal administration of cetrimide and polyvinylpyrrolidone (PVP), with and without ethanol, to the breech and tail. Method A needle‐less injector was used to deposit formulations containing 40 g/L cetrimide and 30 g/L PVP (group 2) or 20 g/L cetrimide, 30 g/L PVP and 15 g/L ethanol (group 3), within the dermis of the tail and the region surrounding the perineal bare breech area of groups (N = 8) of Merino weaner sheep. The dimensions of the perineal bare area (length, width and diagonal distances left and right) and tail width were recorded before and at intervals after treatment for 60 days. Observations of swelling and bruising and scab formation at the treatment sites were recorded for up to 35 days after treatment. Rectal temperatures were monitored for up to 35 days after treatment and bodyweight for up to 60 days after treatment. An untreated control group (group 1) was included. Results Comparison of day ‐3 and day 35 measurement data showed that both treated groups had significantly (P < 0.05) wider breech bare areas compared to the untreated controls and that group 2 sheep had significantly (P < 0.05) longer breech bare areas compared to group 3 sheep or to the untreated controls, which were not significantly different. At this time scabs were still firmly in place on many treated sheep. At day 35 there was no increase in tail bare area caused by either treatment. By day 60 there was no significant difference between the treated and control groups in either the breech or tail regions indicating that the changes present at day 35, were not permanent. Mean weight gain in the groups throughout the 60‐day interval was unaffected by treatment. Intradermal treatment was associated with a significant elevation in body temperature. This effect lasted for 3 days and was associated with signs of discomfort and depressed appearance in at least some of the treated sheep. Bruising was mild to severe in all treated sheep within two days of treatment but was not evident in any sheep by day 21. Mild to moderate swelling was also associated with treatment but was not uniform across sheep in the groups. The tail of one sheep was severely swollen for several days. Swelling remained obvious in most treated sheep until day 14 but was not present at day 21. Conclusion Under the conditions of this study intradermal injection of cetrimide had no permanent effect on bare area measurements on the breech or the amount of wool‐bearing skin on the tail. It also caused signs of discomfort and pain that raise welfare concerns.     

Serum cobalamin concentrations in healthy cats and cats with non-alimentary tract illness in Australia

Objective   To determine a reference range for serum cobalamin concentration in healthy cats in Australia using a chemiluminescent enzyme immunoassay and to prospectively investigate the prevalence of hypocobalaminaemia in cats with non-alimentary tract disease.
Design   Prospective study measuring serum cobalamin concentrations in clinically healthy cats and cats with non-alimentary tract illness.
Procedure   Blood was collected from 50 clinically healthy cats that were owned by staff and associates of Veterinary Specialist Services or were owned animals presented to Creek Road Cat Clinic for routine vaccination. Blood was collected from 47 cats with non-alimentary tract illness presented at either clinic. Serum cobalamin concentration was determined for each group using a chemiluminescent enzyme immunoassay.
Results   A reference range for Australian cats calculated using the central 95th percentile in the 50 clinically healthy cats was 345 to 3668 pg/mL. Median serum cobalamin concentration in 47 cats with non-alimentary tract illness (1186 pg/mL; range 117–3480) was not significantly different to the median serum cobalamin of the 50 healthy cats (1213 pg/mL, range 311–3688). Using the calculated reference range one sick cat with non-alimentary tract illness had a markedly low serum cobalamin concentration.
Conclusion   Although hypocobalaminaemia is uncommon in sick cats with non-alimentary tract illness in Australia, its occurrence in this study warrants further investigation.     

Dietary effect of squid and fish meals on growth and survival of Pacific white shrimp Litopenaeus vannamei in the presence or absence of phytoplankton in an indoor tank system

This study was conducted in 36 indoor 40‐L fibreglass aquaria to determine the weight gain and survival of Litopenaeus vannamei fed different dietary levels of fish (FM) and squid meal (SM) and to evaluate the potential of phytoplankton to reduce FM and SM levels in shrimp feeds. Six experimental isonitrogenous (35% protein) and isocaloric (17.5 kJ g^?1) diets were formulated to contain either 5%, 10% or 20% SM combined with either 6.5% or 12% FM. Dietary effects on growth and survival were compared in two systems: a ‘CLEAR water system’ (CWS) without the presence of microalgae and a ‘GREEN water system’ (GWS) with microalgae in the culture water. Shrimp cultured in the GWS had 28–57% greater weight gain than those cultured in the CWS, regardless of dietary treatment. However, survival was not different. Shrimp cultured in the CWS or the GWS, and fed diets containing combinations of FM and SM did not show differences in weight gain and feed conversion ratio. These results suggest that under the conditions existing during this research, 6.5% FM and 5% SM can be used as a cost‐effective combination in commercial feeds for shrimp production and that growth can be enhanced in the presence of primary productivity.     

Spatial and temporal investigation of Echinococcus granulosus coproantigen prevalence in farm dogs in South Powys, Wales

The prevalence of canine echinococcosis appears to have been increasing in mid/south Wales in recent years - raising the concern of a potential resurgence in transmission to humans. A campaign was therefore conducted in 2008 in order to provide dogs in South Powys with anthelmintics, estimate the coproantigen prevalence amongst these dogs, and evaluate potential risk factors for coproantigen positivity. The coproantigen prevalence identified in these dogs (n=577) was 10.6% (95% confidence interval 7.6-13.5%), with 20.6% (15.6-25.7%) of farms (n=247) containing at least one coproantigen-positive dog. Further spatial investigation identified considerable spatial heterogeneity amongst the farms, with an increased coproantigen prevalence in the regions of Brecknockshire and the Brecon Beacons National Park. Within these areas, there was strong evidence of an increase in coproantigen prevalence, compared to that found in a study conducted in 2002. Finally, a mixed effects logistic regression model identified increased roaming behaviour and decreased dog weight as being associated with increased odds of coproantigen positivity, whereas pet dogs on some farms had similar odds of infection to working dogs. Further surveillance efforts in South Powys are required and should also include the northern areas of Gwent and Glamorgan.